|
LWSN, CERS, MBRK
(M2 PressWIRE Via Acquire Media NewsEdge) New York, NY-- Lawson Software (NASDAQ: LWSN); Cerus Corporation (NASDAQ: CERS); MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK)
StockProfiler.US is Introducing Leading Microcap Companies! We welcome Investors to sign up and subscribe to our FREE Newsletter at www.stockprofiler.us.
-------------------------------------------
Lawson Software closed at $4.87 Monday, trading 1,014,300 shares.
Company News- April 6, 2009: Lawson Software Offers New Application to Help Automate Hospital Supply Replenishment and Capture Patient Charges
Lawson Software (NASDAQ: LWSN) yesterday announced the general availability of Lawson S3 Point of Use, a software application that helps keep healthcare supplies in stock while providing tools to more accurately capture patient charges.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About Lawson Software
Lawson Software provides software and service solutions to 4,500 customers in healthcare, manufacturing, distribution, maintenance, public sector and service sector industries across 40 countries. Lawson's solutions include Enterprise Performance Management, Human Capital Management, Supply Chain Management, Enterprise Resource Planning, Customer Relationship Management, Manufacturing Resource Planning, Enterprise Asset Management and industry-tailored applications. Lawson solutions assist customers in simplifying their businesses or organizations by helping them streamline processes, reduce costs and enhance business or operational performance. Lawson is headquartered in St. Paul, Minn., and has offices around the world. Visit Lawson online at www.lawson.com.
-------------------------------------------
Cerus Corporation closed at $0.665 Monday, trading 63,100 shares.
Company News- April 6, 2009: Cerus Expands INTERCEPT Product Line With New Set for Platelets
Cerus Corporation (NASDAQ: CERS) announced yesterday that it has received CE mark approval for a new configuration of its INTERCEPT Blood System, allowing a single treatment procedure to produce two pathogen inactivated platelet units for transfusion.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The company is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is currently in clinical development.
-------------------------------------------
MiddleBrook Pharmaceuticals, Inc. closed at $1.28 Monday, trading 110,400 shares.
Company News- April 6, 2009: MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for First Quarter 2009 Financial and Operational Results
MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK) announced yesterday it is scheduled to announce its financial results for the 2009 first quarter on Thursday, May 7, 2009, before the market opens.
To read the full news release, go to www.stockprofiler.us, click the Headline Tab, enter the ticker symbol and click the news link.
About MiddleBrook Pharmaceuticals
MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. We have developed a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. We are currently developing a portfolio of anti-infective PULSYS products. Our near-term corporate strategy is to improve dosing regimens and/or reduce frequency of dosing which we believe will result in improved patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG - the first and only FDA-approved once-daily amoxicillin. For more information about MiddleBrook, please visit www.middlebrookpharma.com.
-------------------------------------------
The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Stock Profiler.US, LLC's News Division, which includes but is not limited to www.stockprofiler.us, www.associatesfortune.com, www.businessnetwire.us, www.fastmoneytalk.com, www.markettelegraph.com, www.thewallstreetleader.com, financialbusinessnews.us and www.daytradersdigest.com. Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us.
Keywords: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes, Media Coverage, Google Finance, Google Analytics, Google, Yahoo Finance, Yahoo, MSNBC, Search Engine, AOL Finance, AOL
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS LTD
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
